The diabetic injection used for weight loss — what it is, who it suits, and how to get it safely

Step 1, understand which medicines are licensed for weight loss (and which aren't)

The phrase "diabetic injection" gets used loosely online, which causes real confusion. Ozempic and Rybelsus are both semaglutide, and both are licensed for type 2 diabetes, but neither holds a UK weight-management licence. The medicines that do are Mounjaro (tirzepatide) and Wegovy (injectable semaglutide). Same drug families, different brand authorisations. It matters because the weight-loss injection formulations have been through separate trials and are approved at specific doses for adults who may never have had diabetes at all.

Tirzepatide works on two gut-hormone receptors (GIP and GLP-1) slowing the stomach's emptying and reducing appetite signals. Semaglutide targets the GLP-1 receptor alone. Both slow digestion and help people feel fuller for longer, which is why they were studied for obesity after showing significant weight changes in diabetes trials. If you have come across references to a diabetic injection being used to help with weight loss, our dedicated page explains why those terms overlap and where the licensed boundaries sit. The NHS medicines page on tirzepatide sets out how the drug works in plain language if you want the detail behind the mechanism.

It is also worth knowing that Saxenda (liraglutide), another GLP-1 injection, holds a weight-management licence but is not dispensed by every service. And the overlap between diabetes and weight-loss injections is a topic our prescribers field regularly, the distinction is clinically important, not just a labelling quirk.

Step 2, find out whether the eligibility criteria apply to you

The licensed criteria for both Mounjaro and Wegovy centre on BMI: adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A prescriber does not simply tick the BMI box and approve, they consider the full clinical picture, including other medicines you take and any conditions that would make treatment unsuitable.

NICE's appraisal of tirzepatide (TA1026, updated September 2025) recommends it for NHS use in adults with a BMI of 35 or above alongside at least one weight-related comorbidity, with NHS rollout happening in defined cohorts. Private prescribing follows the licensed criteria, which is broader. If you are unsure where you stand, our page on weight-loss injections for people without diabetes covers eligibility in more detail, or you can browse our clinical FAQs.

The medicines are not recommended for anyone who is pregnant, breastfeeding, or planning to conceive. They are not licensed for use in people under 18. Anyone with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide; pancreatitis history requires a prescriber discussion before starting either medicine. These are clinical conversations, not things to self-assess from a website.

Step 3, access the medicine through a route you can verify

These are prescription-only medicines, which means the only legal route to them in the UK is a prescription issued after a clinical assessment. That assessment can happen via an NHS GP (subject to the current phased rollout criteria), an NHS specialist weight management service, or a regulated private prescriber. Whichever route you take, you should be able to verify the pharmacy on the GPhC register before handing over any personal or payment details.

The MHRA has warned repeatedly about counterfeit weight-loss pens sold online and through social media, fake pens have in some cases contained insulin instead of the labelled medicine, with serious consequences. Some patients also search for less familiar products, and our page on the Mujra weight loss injection addresses what that product is and how it fits within the UK regulatory picture. If a seller is offering these medicines without a prescription or at prices far below anything a legitimate pharmacy could sustain, that is a red flag. The MHRA's Yellow Card scheme allows you to report both suspected side effects and suspect sellers.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not automated software) the same day it is submitted. If the prescription is approved before 12pm on a working day, treatment is dispatched the same afternoon and delivered free the next working day by DPD. The pen arrives in plain, unbranded packaging; you'll get a tracking notification on your phone so you know exactly when it's coming. You can learn more about how our pharmacy works or read about our clinical team's approach.

What to do if you're unsure which option is right for you

The clinical trial evidence for both medicines is substantial. In the SURMOUNT-1 trial, participants using tirzepatide at the highest dose achieved an average body-weight reduction of around 20–21% over 72 weeks, published in the New England Journal of Medicine and cited by NICE in their assessment. Semaglutide at 2.4mg produced an average reduction of around 15% over 68 weeks in the STEP 1 trial. These are group averages from controlled settings; individual results vary and are influenced by adherence, lifestyle changes, and starting weight.

Neither result is guaranteed for any individual, and both medicines work best alongside a reduced-calorie diet and increased activity, the prescriber reviews this as part of treatment. Side effects, particularly nausea and gastrointestinal discomfort, are most common in the early weeks and after each dose increase. The MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients that acute pancreatitis, while infrequent, is a known and potentially serious risk: severe stomach pain that spreads to the back and doesn't ease needs urgent medical attention.

If you are weighing up options or want to understand the differences further, our overview of weight-loss injections compares what is currently available under UK licensing. The right starting point, though, is a conversation with a prescriber who can look at your health in full. Check your eligibility with our clinical team, there's no charge for the consultation.